Checkpoint inhibitors in NSCLC for the elderly: current challenges and perspectives

Area of Science:

• Oncology
• Geriatric Medicine
• Immunotherapy

Background:

• Advanced non-small cell lung cancer (NSCLC) is frequently diagnosed in elderly patients.
• Assessing functional status for traditional chemotherapy in the elderly can be challenging.
• Efficacy and safety data for checkpoint inhibitors in elderly NSCLC patients are limited.

Purpose of the Study:

• To review clinical studies of checkpoint inhibitors in advanced NSCLC patients, focusing on the elderly population.
• To identify specific considerations for using checkpoint inhibitors in older adults with NSCLC.
• To evaluate the efficacy and safety profile of these novel therapies in this demographic.

Main Methods:

• Review of clinical studies involving checkpoint inhibitors in advanced NSCLC.
• Analysis of studies with a significant proportion of elderly patients.
• Inclusion of post-hoc analyses specifically examining elderly cohorts.

Main Results:

• Efficacy data support the use of checkpoint inhibitors in elderly patients with advanced NSCLC.
• The safety profile of all discussed checkpoint inhibitor molecules is deemed acceptable for this age group.
• Checkpoint inhibitors demonstrate potential benefits even in elderly patients with impaired functional status.

Conclusions:

• Checkpoint inhibitors are efficacious and well-tolerated in elderly patients with advanced NSCLC.
• These agents may be suitable for elderly patients with compromised functional status.
• Neoadjuvant checkpoint inhibitor therapy could improve tumor resectability in elderly NSCLC patients.